Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ferrante Karen Jean
Cogent Biosciences | 8-K: Current report
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(9.9%),Point72 Capital Advisors, Inc.(9.9%), etc.
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners II, L.P.(9.99%),VHCP Co-Investment Holdings II, LLC(9.99%), etc.
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Commodore Capital LP(9.3%),Commodore Capital Master LP(9.3%)
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Suvretta Capital Management, LLC(0%),Averill Master Fund, Ltd.(0%), etc.
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Kynam Capital Management, LP(8.36%),Kynam Capital Management GP, LLC(8.36%), etc.
Cogent Biosciences | 10-Q: Q3 2024 Earnings Report
Cogent Biosciences | 8-K: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(12.068%),Abigail P. Johnson(12.068%)
Cogent Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(7.601%),Abigail P. Johnson(7.601%)
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ferrante Karen Jean
Cogent Biosciences | 8-K: Current report
Cogent Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Cogent Biosciences | 10-Q: Q2 2024 Earnings Report
Cogent Biosciences | 8-K: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ferrante Karen Jean
Cogent Biosciences | 8-K: Current report
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director CAIN CHRISTOPHER W.
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew